ReShape Lifesciences
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 31
- Market Cap
- -
- Introduction
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
ReShape Vest™ for the Treatment of Obesity (Europe)
- Conditions
- ObesityWeight Loss
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- ReShape Lifesciences
- Target Recruit Count
- 65
- Registration Number
- NCT03918564
- Locations
- 🇪🇸
Hospital universitario de Bellvitge, Barcelona, Spain
vBloc Now - Registry
- Conditions
- Obesity, Morbid
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- ReShape Lifesciences
- Target Recruit Count
- 125
- Registration Number
- NCT03434522
- Locations
- 🇺🇸
Sky Ridge, Lone Tree, Colorado, United States
🇺🇸Christiana Institute of Advanced Surgery, Newark, Delaware, United States
The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol
- Conditions
- Obesity, Morbid
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- ReShape Lifesciences
- Target Recruit Count
- 4
- Registration Number
- NCT03145636
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects
- Conditions
- Obesity
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- ReShape Lifesciences
- Target Recruit Count
- 186
- Registration Number
- NCT02927665
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Christiana Institute of Advanced Surgery, Newark, Delaware, United States
🇺🇸Barrington Surgeons, Barrington, Illinois, United States
A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
- Conditions
- Obesity
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- ReShape Lifesciences
- Target Recruit Count
- 326
- Registration Number
- NCT01673698
- Locations
- 🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Hamilton Medical Center, Dalton, Georgia, United States
🇺🇸Marquette General Surgical Weight Loss Center, Marquette, Michigan, United States
- Prev
- 1
- 2
- Next
News
Vyome Therapeutics Secures Nasdaq Approval for Merger with ReShape Lifesciences, Targeting $100B Inflammatory Disease Market
Vyome Therapeutics received Nasdaq approval for its merger with ReShape Lifesciences, set to begin trading as "HIND" on August 15, 2025.
ReShape Lifesciences Achieves Early EU MDR Certification for Obesity Treatment Devices
ReShape Lifesciences secured EU MDR and UK Conformity Assessment certification for its entire commercial portfolio of medical devices, achieving compliance well ahead of the December 31, 2027 regulatory deadline.
ReShape Lifesciences Announces Merger with Vyome and Asset Sale to Biorad Amid Q1 2025 Financial Results
ReShape Lifesciences reported Q1 2025 financial results showing revenue of $1.1 million, a 42.7% decrease from the same period in 2024, primarily due to competition from GLP-1 pharmaceutical weight-loss alternatives.
ReShape Lifesciences' Diabetes Neuromodulation Device Shows Promise in Preclinical Studies
ReShape Lifesciences presented preclinical data demonstrating their proprietary Diabetes Neuromodulation device can effectively reverse insulin-induced hypoglycemia without cardiac side effects in a swine model of Type 1 diabetes.